There is no international body that regulates stem cell therapy, so whether it is legal depends on the country, and each one sets its own rules about what is permitted. In Mexico, expanded mesenchymal stem cell (MSC) therapy is regulated by COFEPRIS and Panama puts it on a research track under MINSA, while Cayman offers it inside an IRB clinical study, Germany under a PEI Hospital Exemption approval, Japan through its two regenerative-medicine laws, and Colombia only inside INVIMA-approved trials.
Find a country on the mapThe international landscape for cell therapy isn't one block of "abroad." It's six distinct national frameworks, each with its own regulatory body, its own legal basis, and its own rules about what's permitted. Between them they use several operating models, from regulated hospital care to an IRB clinical study to conditional marketing approval.
Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). Established 2001, a body of the health ministry.
Mexico's General Health Law.
Expanded allogeneic mesenchymal stem cell therapy, regulated by COFEPRIS and given by qualified physicians. Programs like Celva's give it inside a hospital, by IV and by direct local application (joint and spine).
Manufacturing standard: NOM-059-SSA1-2015, Mexico's Official Norm for GMP.
Mexico is among the top global destinations for medical tourism, with about 1.2 million U.S. patients a year by Patients Beyond Borders' estimate. Tijuana, Mexico City, Cancún, Guadalajara, and Monterrey are among the cities they travel to. Tijuana, where Celva operates, is the destination most accessible to U.S. West Coast patients.
Care regulated by a federal agency, with a substantial international patient base. The default for Americans shopping the international landscape, and the framework most of this Learn library is written under.
Ministerio de Salud (MINSA), the Panama Ministry of Health.
Cell therapy in Panama runs on a research track. Executive Decree 179 of 2018 regulates research with human cells and tissues, and uses outside transplant need a protocol authorized by the national research bioethics committee.
Expanded allogeneic MSC therapy, particularly cord-derived cells, under that research-track model. Panama has been a recognized international destination for stem cell therapy since the late 2000s.
Stem Cell Institute Panama (SCI), founded by Neil Riordan, PhD. Affiliated with Medistem Panama (MPI), its laboratory in the City of Knowledge research park.
SCI reports more than 80,000 procedures and more than 20,000 patients over about 20 years. Self-reported figures, not independently audited.
Read the Stem Cell Institute comparison →
A national ministry and a research-track decree, with one dominant program rather than the broader clinic ecosystem Mexico has built around Tijuana, Cancún, and Mexico City.
Health Practice Commission of the Cayman Islands. IRB-approved study oversight.
Cell therapy in Cayman is structured differently from Mexico or Panama. Treatment is offered under U.S.-IRB-approved clinical study protocols, with the protocol registered with the Government of the Cayman Islands. The patient is enrolled in what is positioned as a patient-funded clinical study rather than receiving an approved commercial therapy.
DVC Stem in Grand Cayman, under IRB-approved study protocol HPC/CTR/003, "Evaluation of Cultured Expanded Allogeneic, Cord-Derived Mesenchymal Stem Cells, Deployed via Intravenous Injection for Safety and Effect on Systemic Inflammation."
DVC Stem's cells are manufactured in a U.S.-based partner laboratory: FDA-registered, cGMP-compliant, ISO 9001 and ISO 13485 certified, AATB-certified tissue donors. Cells made under U.S. quality standards; administered in Cayman under the IRB study protocol.
Positioned as more conservative on the regulatory side: cells made under U.S. cGMP, administered as part of an IRB-approved study rather than as approved commercial therapy. The trade-off: the patient is in a study framework, not a clinical-care framework.
The shape of Cayman's model is the structural argument for Cayman: U.S.-made cells, U.S.-IRB-monitored. The structural argument against is the same observation said differently: the patient is being treated inside a study, not under commercial medical care.
Paul-Ehrlich-Institut (PEI), the German Federal Institute for Vaccines and Biomedicines. §77 of the Drug Law (AMG).
EU Regulation 1394/2007 introduced the "Hospital Exemption," allowing EU member states to regulate non-routinely-manufactured ATMPs (advanced therapy medicinal products) under their own national laws. Germany implemented this in July 2009.
Cell therapy under a PEI hospital-exemption approval for preparations that are not routinely manufactured, under specific clinical conditions. More restrictive than Mexico or Panama, but permits some categories of treatment the U.S. FDA framework does not.
Section 4b of the German Drug Law specifies the pathway permitting hospitals with a Hospital Exemption approval to produce and administer cell-based products that are not routinely manufactured.
A regulator-purist alternative for patients willing to trade Mexico's accessibility for the narrower, EU-grounded Hospital Exemption framework.
PMDA (Pharmaceuticals and Medical Devices Agency) and MHLW (Ministry of Health, Labor and Welfare). Both laws in force since November 2014.
Two laws, passed in 2013 and in force since November 2014. The Act on the Safety of Regenerative Medicine (RM Act) covers clinical research and medical practice using processed cells. The Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) introduces a specific regulatory framework for regenerative medicine products.
The PMD Act introduces conditional and time-limited marketing approval. After exploratory trials demonstrate probable benefit and proven safety, a product can receive conditional approval allowing immediate marketing and use. The sponsor must then continue to collect efficacy data for up to seven years to convert conditional approval to full approval.
Temcell HS Injection: allogeneic MSC product for acute GvHD, the first allogeneic regenerative medicine product to receive full PMD Act approval (Sept 2015). HeartSheet: skeletal myoblast sheet for severe heart failure; conditionally approved in 2015 and refused full approval in 2024 because efficacy was not shown. STEMIRAC: autologous bone-marrow MSC product for spinal cord injury; conditionally approved in 2018.
Japan's pathway is the most explicitly forward-leaning of the regulatory-purist alternatives. The conditional-approval framework was designed specifically to give patients earlier access to regenerative medicine products while continuing to collect efficacy data.
A different shape entirely. Japan grants approval to products, not licenses to clinics. For a U.S. patient evaluating destinations, Japan reads less like "a place to go" and more like "a regulatory architecture worth understanding by contrast."
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia's national regulator for medicines, biologics, and clinical trials.
Decree 2493 of 2004. Hematopoietic stem cell transplants may be performed only by authorized transplant centers using cells from INVIMA-licensed banks. Treatments with cultured or expanded MSC are not approved for routine clinical use; they may be offered only within INVIMA-authorized clinical trials with ethics committee oversight.
A market where the letter of the regulation and the practice of the clinics have drifted apart. Not disqualifying, many of the Colombian operators are serious, but the verification burden falls on the patient.
BioXcellerator in Medellín: Phoenix, AZ-headquartered, operating clinical operations in Colombia. INVIMA approved a clinical trial proposal from BioXcellerator for COVID-19 use of MSCs. The clinic operates an onsite GMP-certified laboratory and has published peer-reviewed safety research on intrathecal MSC delivery.
Read the BioXcellerator comparison →
Treat Colombia as a market where the question "is this specific clinic operating inside the regulation" is the question, not "is the country regulated."
There is no "international body" that regulates stem cell therapy. Every country builds its own framework, and the gap between permitted and enforced is one of the most important things to learn about any of them.
Germany's framework is genuinely enforced. The XCell-Center in Düsseldorf and Cologne was closed by German authorities in 2011, following enforcement action after the death of an 18-month-old patient from internal bleeding after intracranial stem cell injection.
The XCell case demonstrated that the German framework permits cell therapy under specific conditions but does not tolerate operators outside those conditions. A meaningful contrast to enforcement patterns elsewhere on this map.
HeartSheet held a conditional approval from 2015. In 2024 full approval was refused because efficacy was not shown. The case demonstrates conditional approval is genuinely conditional.
Multiple sources note that enforcement of Colombia's expanded-MSC restrictions has been inconsistent. Treatments are commonly offered commercially despite the technical requirement that they be administered only within INVIMA-approved trials.
Patients evaluating Colombian clinics should verify that the specific clinic is operating under either an INVIMA-approved trial or appropriate licensing for what they're offering.
Each operates its own regulatory framework with varying levels of rigor and varying clinical reputations. Patients evaluating these markets should verify the specific regulatory body, the clinic's licensing status, and the operating model with the same diligence applied to any other international destination. We don't have the primary-source depth on these markets to characterize them in detail.
These markets operate under regulatory frameworks roughly comparable to FDA / EMA. Cell therapy access is primarily through clinical trials rather than commercial clinic practice. Useful as contrast points showing that the U.S. is not alone in its regulatory posture: multiple other developed markets have made similar choices.
The countries above aren't worse destinations than the six on the map, just less characterized on this page. If you're evaluating one of them, ask the clinic the same five questions this page asks of every country.
This page doesn't rank them. Patients seeking expanded MSC therapy outside the U.S. are choosing between regulated systems with genuinely different rules, not between "regulation" and "no regulation." The country choice has real consequences for licensing, oversight, and what the operating model of the actual clinic looks like.
Whichever country you're weighing, the five questions are the same.